MUC16 and neoplasm: T cell activation, INF-γ and IL-2 secretion, as well as induced bystander killing of non-infected tumor cells were observed.193 Oncolytic Ads armed MUC16-BiTE targets highly glycosylated mucins that are overexpressed in ovarian cancers, leading to the improvement of MHC I antigen presentation, the proliferation and activation of T cells, the cytotoxicity against MUC16+ tumor cells, as well as remodulation of the TME.194 Other strategies such as ICOVIR-15K-cBiTE195 and MV-BiTEs196 have similar effects.